>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey B7-1/CD80
is immobilized at 0.5 µg/mL
(100 µL/well), the concentration of Recombinant Human CTLA-4 Fc Chimera
(Catalog # 7268-CT)
that produces 50% of the optimal binding response is approximately 5-30 ng/mL.
Human embryonic kidney cell, HEK293-derived Val35-Asn242, with a C-terminal 6-His tag
When Recombinant Cynomolgus Monkey B7-1/CD80 (Catalog # 9244-B1) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human CTLA-4 Fc Chimera (Catalog # 7268-CT) binds with an ED50 of 5-30 ng/mL.
B7-1/CD80 and B7-2/CD86, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses (1). Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20 - 100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response (2-6). Mature cynomolgus B7-1 consists of a 208 aa extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane domain, and a 25 aa cytoplasmic domain (7). Within the ECD, cynomolgus B7-1 shares 97%, 51%, and 54% aa sequence identity with human, mouse, and rat B7-1, respectively. Both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4 (1). B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells (2).
Ville, S. et al. (2015) Front. Immunol. 6:411.
Azuma, M. et al. (1993) Nature 366:76.
Freeman, G.J. et al. (1993) Science 262:909.
Chen, C. et al. (1994) J. Immunol. 152:4929.
Freeman, G.J. et al. (1993) J. Exp. Med. 178:2185.